Cross-Reactivity Between Penicillin and Other Antibiotics

Penicillin allergy is one of the most frequently reported drug hypersensitivities worldwide, affecting approximately 10% of the general population. However, true immunologic allergy to penicillin is far less common than recorded, and misconceptions about cross-reactivity with other β-lactam antibiotics often lead to unnecessary avoidance of effective treatments. A review of recent research provides a clearer understanding of the mechanisms and actual risks of cross-reactivity between penicillin and other antibiotic classes, particularly cephalosporins, carbapenems, and monobactams.

Cross-reactivity between penicillin and other β-lactams primarily arises from similarities in their chemical structures. While these antibiotics share a core β-lactam ring, the immune system most often recognizes and reacts to the unique side-chain structures attached to this core, rather than the β-lactam ring itself. Therefore, antibiotics that share similar side chains are more likely to trigger allergic responses in sensitized individuals. For instance, certain aminopenicillins and first-generation cephalosporins share similar side chains, which can increase the likelihood of cross-reactivity, whereas agents with distinct side chains carry a much lower risk.

Cephalosporins have historically been regarded as risky alternatives for patients with penicillin allergy, with earlier studies suggesting a 10% cross-reactivity rate. Modern research, however, indicates that this figure was significantly overestimated. Current data show that when cephalosporins with different side chains are used, the true cross-reactivity rate is closer to 1–2%. The highest risk occurs with cephalosporins that share identical or highly similar side chains to the culprit penicillin, such as ampicillin and cefadroxil. Later-generation cephalosporins, such as ceftriaxone or cefepime, have structurally distinct side chains and are generally considered safe for use in most patients with penicillin allergy, provided the allergic history is not severe or life-threatening.

Carbapenems, another class of β-lactam antibiotics, show an even lower rate of cross-reactivity with penicillin. Although early studies reported cross-sensitivity rates as high as 10%, more recent investigations using validated allergy testing methods estimate the risk at less than 1%. This evidence suggests that carbapenems can often be safely administered to penicillin-allergic patients, except in cases of severe delayed hypersensitivity reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis. As a result, carbapenems have become a viable option in patients requiring broad-spectrum coverage when allergy to penicillin is reported.

Monobactams, represented primarily by aztreonam, are unique among β-lactams due to their distinct monobactam ring structure. Studies have shown virtually no cross-reactivity towards aztreonam in patients with confirmed penicillin allergy. The notable exception is in patients allergic to ceftazidime, which shares an identical side chain with aztreonam, potentially increasing the risk of cross-reactivity. Overall, monobactams remain one of the safest alternatives for patients with true IgE-mediated penicillin allergy who require β-lactam therapy.

From a clinical perspective, accurate assessment and documentation of penicillin allergy are essential. Many individuals labeled as allergic to penicillin have never experienced a true allergic reaction or have lost their sensitivity over time. Distinguishing between mild adverse reactions and genuine IgE-mediated hypersensitivity is critical for safe antibiotic selection. Skin testing, oral challenge protocols, and structured allergy evaluation can identify patients who may safely receive penicillin or related antibiotics, thereby avoiding unnecessary use of broad-spectrum agents such as fluoroquinolones or vancomycin.

In conclusion, contemporary evidence demonstrates that cross-reactivity between penicillin and other β-lactam antibiotics is far less frequent than once believed. The principal determinant of risk lies in side-chain similarity rather than the β-lactam ring structure itself. Cephalosporins with distinct side chains, carbapenems, and monobactams can often be used safely in appropriately evaluated patients with reported penicillin allergy. Reassessing and delabeling inaccurate penicillin allergies not only improves antibiotic stewardship but also enhances patient outcomes and reduces healthcare costs.

References

1. Romano A, Gaeta F, Valluzzi RL, et al. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T-cell–mediated hypersensitivity to penicillins. J Allergy Clin Immunol. 2016;138(1):179-186. DOI: 10.1016/j.jaci.2016.01.025
2. Fernández-Santamaría R, Ariza A, Montañez MI, et al. Penicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes. Clin Transl Allergy. 2020;10:57. DOI: 10.1186/s13601-020-00368-1
3. Lee Y, Bradley N. Overview and insights into carbapenem allergy. Pharmacy (Basel). 2019;7(3):110. DOI: 10.3390/pharmacy7030110
4. Romano A, Viola M, Montuschi P. Beta-lactam hypersensitivity and cross-reactivity. Allergy Asthma Immunol Res. 2014;6(6):485-498. doi:10.4168/aair.2014.6.6.485
5. Vyles D, Chiu A, Adkinson NF Jr. Cross-reactivity among beta-lactams. J Allergy Clin Immunol Pract. 2016;4(5):e1-114. DOI: 10.1177/0897190014546109